Loading...
XNYS
HAE
Market cap4.10bUSD
Dec 05, Last price  
83.94USD
1D
0.16%
1Q
54.36%
Jan 2017
108.81%
Name

Haemonetics Corp

Chart & Performance

D1W1MN
XNYS:HAE chart
P/E
24.43
P/S
3.01
EPS
3.44
Div Yield, %
Shrs. gr., 5y
-0.42%
Rev. gr., 5y
6.60%
Revenues
1.36b
+3.95%
419,733,000449,607,000516,440,000597,879,000645,430,000676,694,000727,844,000891,990,000938,509,000910,373,000909,675,000886,116,000903,923,000967,579,000988,479,000870,463,000993,196,0001,168,660,0001,309,055,0001,360,824,000
Net income
168m
+42.64%
69,076,00049,109,00051,980,00059,304,00058,375,00079,980,00066,886,00038,800,00035,148,00016,897,000-55,620,000-26,268,00045,572,00055,019,00076,526,00079,469,00043,375,000115,401,000117,558,000167,679,000
CFO
182m
-0.01%
85,616,00083,563,00077,669,000116,364,000130,668,000123,455,000115,318,00085,074,000139,524,000127,178,000121,865,000159,738,000220,350,000159,281,000158,217,000108,805,000172,263,000273,058,000181,751,000181,725,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
IPO date
Oct 17, 1979
Employees
3,034
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT